Q-omics provides the consensus-scored CD247 profile across patient tissues and cancer cell-line models. CD247 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD247 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CD247 RNA expression shows 17,928 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CD247 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD247 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD247 survival associations across molecular data types. CD247 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD247 RNA expression–survival associations across cancer types. High CD247 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, UCEC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD247 RNA expression.
This table summarizes CD247 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD247. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD247 shows lower tumor expression in COAD, LUSC and LUAD and higher tumor expression in KIRC, STAD and HNSC. The KIRC box plot shows higher CD247 RNA expression in tumor versus normal tissue (log2 FC = +2.152, t-test p < 0.001).
This table shows molecular features associated with CD247 in patient tissues and cancer cell lines. In patient samples, CD247 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD247 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
